Hologic executed a settlement agreement on January 7, 2026, resolving claims by approximately 200 plaintiffs over its recalled BioZorb breast tissue marker, ending a consolidated District of Massachusetts proceeding before Judge Allison D. Burroughs without any admission of liability. The settlement followed a February 2024 FDA safety communication, two Class I recalls, an FDA warning letter, and bellwether summary judgment rulings that split on surgeon deposition testimony, mirroring other recalled implant disputes.
This analysis covers BioZorb's regulatory path, the 2024 recall record, the consolidated litigation, dispositive causation rulings, proof issues, and practice implications for future 510(k) implant cases.
A Class II Marker That Never Faced PMA Review
BioZorb pairs a bioabsorbable polylactic acid (PLA) spacer with six permanent radiopaque titanium clips, implanted at the excision site so radiologists and radiation oncologists can target the lumpectomy cavity. The spacer is designed to resorb through hydrolysis, leaving the clips as permanent markers.
Focal Therapeutics obtained the original clearance, K113202, on February 28, 2012, filed under the device name Tissue Marker and cleared as substantially equivalent. Later clearances followed in 2015 and 2019. The device stayed a Class II product under 21 CFR 878.4300.
Hologic acquired Focal Therapeutics for $125 million in cash. The transaction closed on October 1, 2018, per its Form 8-K. The purchase added BioZorb to Hologic's Breast Health portfolio, where it remained until Hologic's own 2024 stop-ship notice ended distribution.
Two Class I BioZorb Recalls in Eight Months: The 2024 Enforcement Record
The recall unfolded in stages over eight months, and injury counts differ by document and date. The FDA classified both actions as Class I, its most serious category, but recorded a different cause and a different remedy for each.
- February 27, 2024: The FDA published the safety communication on BioZorb adverse events that the bellwether orders later cite as the FDA Safety Communication. No numeric injury count accompanied it.
- March 13, 2024: Class I correction recall Z-1733-2024, posted May 3, 2024, covered all lots across nine model numbers, including implanted devices. A correction updates labeling and communications; devices remained on the market. The FDA recorded the cause as unknown or undetermined by the firm.
- September 29, 2024: Hologic issued a stop-ship notice and ceased manufacturing.
- October 10, 2024: Hologic initiated Class I removal recall Z-0328-2025, pulling all unused lots, with recall letters dated October 24 and FDA posting on November 26. The FDA issued a Do Not Use safety communication on October 25. The FDA attributed the recall cause to "Device Design" and counted 252 injuries and zero deaths.
The FDA's December 18, 2024 warning letter to Hologic, MARCS-CMS 698214, following an inspection running July 30 to September 24, 2024, found that Hologic's design history file omitted a resorption timeline and failed to address how in vivo radiation treatments affect performance. It also found that a CAPA responding to a September 2023 complaint spike was not opened until May 2024, because the CAPA procedure escalated only complaints rated severity 4 (critical) or 5 (catastrophic). One cited complaint reported a device that failed to dissolve for almost five years.
Rule 42(a) Consolidation Without JPML Transfer
Judge Burroughs consolidated the cases under Federal Rule 42(a) into the first-filed District of Massachusetts docket, No. 22-cv-11895, and under the caption In re BioZorb Device Products Liability Litigation (D. Mass. 2025). The consolidation order entered at ECF No. 121. The Judicial Panel on Multidistrict Litigation did not transfer the cases.
The court limited phase one to document discovery and depositions of plaintiffs and their implanting physicians, so that summary judgment motions would reach only the learned-intermediary doctrine as applied to causation on each failure-to-warn claim. Four bellwether trial-pool plaintiffs were selected, among them Cynthia Kresch, Beth Deuel, and Pamela Gibson. None reached trial before the November 2025 stay ended the schedule.
The court's September 26, 2024 order counted more than eighty plaintiffs across eighteen cases. By January 29, 2026, Hologic's Q1 FY2026 10-Q reported approximately 200 plaintiffs, one pending in Massachusetts state court and the remainder in federal court.
Why 510(k) Clearance Left Design and Warning Claims Open
Had BioZorb gone through premarket approval, many claims would likely have faced dismissal. Under Riegel v. Medtronic, Inc., 552 U.S. 312 (2008), PMA imposes "specific requirements applicable to a particular device," and 21 U.S.C. § 360k(a) then bars state-law claims that would add different or additional requirements. Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996), held that "the 510(k) process is focused on equivalence, not safety."
That left no device-specific safety finding for state tort law to conflict with. The published BioZorb orders turn on learned-intermediary causation, pleading sufficiency, and expert reliability rather than express preemption, consistent with Lohr leaving express preemption unavailable for a 510(k)-cleared Class II device.
Two doctrines still narrow the field:
- Buckman Co. v. Plaintiffs' Legal Committee, 531 U.S. 341 (2001), impliedly preempts state-law fraud-on-the-FDA claims; parallel claims premised on violating existing federal requirements survive.
- Compliance-presumption statutes narrow warning claims in some states. Michigan's § 600.2946(4) presumes non-liability where the aspect of the product that caused the harm complied with federal standards or carried federal agency approval. New Jersey's § 2A:58C-4 reaches devices expressly and presumes an FDA-approved warning adequate. Rebutting the New Jersey presumption requires pleading deliberate concealment of after-acquired knowledge or manipulation of the post-market regulatory process, which pushes plaintiffs toward the theory Buckman limits.
How Surgeon Testimony Decided the Failure-to-Warn Rulings
Between September 2024 and February 2025, the court ruled on failure-to-warn summary judgment for eight plaintiffs across five orders, and every outcome tracked the implanting surgeon's testimony. Plaintiffs whose surgeons said a stronger warning could have changed the implant decision survived; plaintiffs whose surgeons said otherwise, or who produced nothing, lost.
- September 26, 2024 (ECF No. 170): Denied as to Melkonian, Willard, and Ensley; granted against Burke because Florida recognizes no heeding presumption and she offered no evidence her surgeon would have decided differently.
- January 3, 2025 (the Rishell summary-judgment order, ECF No. 202, relating to No. 1:23-cv-10260): Denied on failure to warn after the order reported that Rishell's implanting surgeon, Dr. John Turner, testified that knowledge of the risks "could have" led him "not [to] implant the BioZorb device in Ms. Rishell." The implied-warranty count was granted for Hologic.
- January 15, 2025 (the Kresch summary-judgment order): Denied; the order recounted testimony from Kresch's implanting surgeon, Dr. John Rinkliff, that "the longer we used [the BioZorb], the more we were realizing that this thing [was] not going away as fast as we thought it was."
- February 3, 2025 (the Deuel summary-judgment order): Granted; the order reported that Deuel's implanting surgeon, Dr. Stephen Cahill, a board-certified general surgeon, would have used BioZorb even knowing the complications described in the FDA Safety Communication.
- February 14, 2025 (the Gibson summary-judgment order, ECF No. 225): Granted; Colorado applies no heeding presumption.
Design-defect claims cleared their own hurdle on March 14, 2025, when the court denied dismissal across five cases. The court held that "the allegation that the BioZorb does not provide a therapeutic advantage over ordinary titanium clips satisfies the requirement that a proposed alternative not undermine the utility of the product." Hologic's challenges to the reliability of plaintiffs' causation experts were still pending when the November 2025 settlement stay mooted them, so no merits ruling on expert admissibility issued.
The Records That Carried the Causation Burden
Because the dispositive testimony came from implanting surgeons, counsel had to assemble the full record before each deposition. Four proof categories recurred across the bellwether record:
- Operative and pathology reports establishing implantation. The lumpectomy operative note, with its device sticker, tied a patient to a recalled unit.
- Model and lot identification. Counsel cross-referenced the model number against the nine recalled part numbers (F0202, F0203, F0303, F0304, F0221, F0231, F0331, F0404, F0405) listed in the FDA recall record and safety communication.
- Imaging documenting non-resorption or migration. Labeling stated the device should completely resorb within one or more years, while the FDA warning letter cited a complaint reporting a device that had not dissolved after almost five years, and Hologic sent clinicians a follow-up notification on April 6, 2026, addressing patients still carrying implanted markers. Baz et al. (Ochsner Journal, 2026) reviewed 296 patients and found 13, or 4%, with device-related complications, 62% of whom had the device removed, chronic pain being the most common finding at 54%.
- Infection, revision, and explant records. In August 2022, months after implantation, Rishell required surgery to remove the device after an infection and after it broke through her skin. Deuel underwent a third surgery to remove her marker in May 2022, and testified her symptoms abated afterward.
These records spanned surgery, radiation, chemotherapy, and years of surveillance imaging. Completeness governs expert exposure on reliability: a causation opinion that cannot place the device at the site of the injury, or cannot rule out pain from the lumpectomy and radiation themselves, invites challenge.
A Confidential Global Settlement and a Recall the FDA Has Not Closed
In November 2025, the parties reached an agreement in principle and disclosed it to the court, which stayed the bellwether schedule. Hologic executed the settlement agreement on January 7, 2026 and disclosed it in a Form 8-K. Settlement terms remain confidential; no dollar figure appears in any SEC filing or court record.
Hologic's disclosures include no admission of liability. They state that the settlement amount is "fully covered by insurance," with Hologic expecting "no financial liability." The agreement carries a participation threshold analogous to a class action opt-out threshold, which, if satisfied along with the other conditions, produces dismissal with prejudice of the substantial majority of BioZorb cases.
The FDA still lists Recall Z-0328-2025 with a status of open and classified, and its September 2023 draft guidance on evidentiary expectations for 510(k) implants, issued months before the first recall, remains in draft. The settlement resolved the plaintiffs' claims without resolving the clearance questions, the same pattern documented in prior mass tort settlements and textured device litigation.
What the BioZorb Workup Transfers to the Next 510(k) Implant Matter
Plaintiffs' counsel should screen for heeding-presumption law at intake, since Colorado and Florida plaintiffs lost on that gap before records investment could matter. Before the implanting-surgeon deposition, counsel should assemble the full medical chronology, from operative note through explant pathology, because the difference between "could have reconsidered" and "would have proceeded regardless" separated the surviving claims from the dismissed ones. Device stickers should be traced to recalled part numbers early; an FDA-determined "Device Design" recall cause anchors the design-defect pleading once device identity is confirmed.
Defense counsel should focus resources on causation and Daubert motions in 510(k) matters. For a comparable device docket where causation and device identification drove the record, see this analysis of MDL 3081.
